Shuyuan Yao, PhD

Dr. Shuyuan Yao serves as CEO of Allogene Overland Biopharm (PRC) Co., Ltd. from June 2021. Prior to Allogene Overland, he served as Chief Scientific Officer, Head of Research & Technology Development of Advanced Therapies Unit (ATU) at WuXi AppTec where he led new technology acquisition, development, translation and application. From May 2018, Dr. Yao served as the VP of Operations at WuXi AppTec and General Manager of WuXi ATU Co., Ltd, establishing the new subsidiary company, ATU China. At the start of his tenure at WuXi AppTec, he established and directed the Cell Therapy R&D business unit focusing on CAR-T cell therapy development from 2014. He oversaw the rollout of this business unit to create JW Therapeutics (Shanghai) Co., Ltd, a joint venture between WuXi AppTec and Juno Therapeutics, which was listed on the HKSE in Nov.2020, serving as VP of Operations.

Dr.Yao has established and managed several start-up projects and companies and has profound experiences in R&D, manufacturing, facility, team and project management. He started his pharmaceutical career at Sangamo Biosciences, later transitioning to various roles of increasing responsibility at Stemgent, CalCyte Therapeutics, and the Allen Institute for Brain Science. He was Associate Director of Biology at Vertex Pharmaceuticals R&D (Shanghai) Co., Ltd. before joining in WuXi AppTec.

Dr.Yao received his Ph.D. degree on Molecular & Medical Genetics from University of Toronto School of Medicine, accomplished postdoctoral training in stem biology at The Scripps Research Institute (TSRI). He graduated from Wuhan University,China.